To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:6 Issue:1 Number:48 ISSN#:2564-2537
Author Verified
ACE Report #9245
Ace Report Cover Metabolic Disorders

Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates

How to Cite

OrthoEvidence. Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates. ACE Report. 2017;6(1):48. Available from:

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

Contributing Authors:
PD Miller N Pannacciulli JP Brown E Czerwinski BS Nedergaard MA Bolognese J Malouf HG Bone JY Reginster A Singer C Wang RB Wagman SR Cummings

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


643 postmenopausal women with osteoporosis who had used oral bisphosphonate for a minimum of 2 years were randomized to either subcutaneous injections of denosumab 60mg - one at baseline and another at 6 months - or intravenous injection of zoledronic acid 5mg. The purpose of this study was to evaluate if denosumab offered noninferior or superior efficacy and safety to zoledronic acid for increasi...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.